CASE REPORT Thoracic cord compression due to ligamentum flavum gouty tophus: a case report and literature review

Z-F Zheng¹, H-L Shi², Y Xing¹, D Li¹, J-Y Jia¹ and S Lin¹

Study design: Here we describe a patient who developed myelopathy due to gouty tophi of the ligamentum flavum in the thoracic spine. We also review similar cases previously reported in the literature.

Objective: Our aim was to present a case of myelopathy due to thoracic spinal gouty tophus.

Methods: We report the case of a 56-year-old male with history of peripheral gout and renal insufficiency. The patient complained of back pain and paraparesis of the left lower limb. Multiple tophi were noted over several interphalangeal and metatarsophalangeal joints. Neurological examination showed decreased left lower limb strength and a positive Babinski sign. Magnetic resonance imaging of the thoracic spine revealed hypertrophy of the ligamentum flavum at the level of T3/T4, T5/T6, T9/T10, T10/T11 and T11/T12.

Results: A thoracic laminectomy at T1-T5 was performed. Chalky white granular material was found in the ligamentum flavum during surgery. Histological analysis of the specimen demonstrated a gouty tophus. The patient's back pain and paraparesis of the lower left limb improved.

Conclusion: The clinician should include spinal gout in the differential diagnosis when dealing with patients with gout and axial pain with or without neurologic deficits. If this diagnosis is seriously entertained, then a CT scan or magnetic resonance imaging as well as tissue biopsy may be needed to establish the diagnosis.

Spinal Cord (2015) 53, 881-886; doi:10.1038/sc.2015.93; published online 16 June 2015

BACKGROUND

Gout is monosodium urate crystal-induced inflammatory arthritis associated with hyperuricemia.¹ The incidence of gout is estimated to be 0.2–0.4% worldwide, with an annual incidence of 0.01–0.015%.² Gout is more common in men with a male-to-female ratio of 4:1 below the age of 65 years and 3:1 above the age of 65 years.³ Predisposing factors for an acute attack include trauma, surgery, increasing alcohol intake, high levels of intake of meat and fish and medications including diuretics and cyclosporine. Tophaceous gout is characterized by precipitation of urate crystals in the joints and periarticular tissues, and deposits commonly are found in the metatarsophalangeal joints, ankles, knees, wrists, fingers and shoulders. Gouty arthritis of the axial joints, particularly of the spine, is very rare.

Gout could involve all the segments of the spine. King *et al.* reviewed the records of reported cases of axial gouty tophi and ~44% of the axial gout patients had involvement of the lumbar vertebrae, 39% the cervical vertebrae and 17% the thoracic vertebrae.⁴ Tophaceous gout could impact anatomic components of the spine, such as facet joint,⁵ vertebral bodies,⁶ pedicle,⁷ lamina⁸ and ligamentum flavum.⁹ Patients present with features of spinal stenosis, lumbar radiculopathy, spondylolisthesis, cauda equine syndrome or spinal infection.

We present a case of a newly diagnosed patient with thoracic spine tophaceous gout involving the ligamentum flavum.

CASE PRESENTATION

A 54-year-old Chinese male with a 12-year history of gout and hyperuricemia reported a 3-day history of lower limb edema and elevated serum creatinine. He suffered episodic gouty attacks, despite intermittently being treated with nonsteroidal anti-inflammatory drugs. Tophaceous deposits were present in the hands and toes for at least 5 years. Furthermore, the patient reported high alcohol intake spanning 20 years. He denied any history of trauma or spinal injuries. After he had been admitted to inpatient ward, he was found to have tenderness in the left anterior leg with anesthesia. Five days later, he complained of progressive back pain radiating to his anterior chest. The level of skin anesthesia increased from the lower extremities to his chest. Several days later, the paraparesis progressed to difficulty walking.

On physical examination the patient was found to have a fever of 38.8 °C. He had significant tenderness in his back and obvious difficulty with ambulation secondary to pain. Multiple tophi were also noted over several interphalangeal joints and metatarsophalangeal joints. Neurological examination showed that his lower limb strength had decreased (Grade 4/5) on the left and he had left ankle clonus. The lower abdominal and cremasteric reflexes were normal. The left lower limb also showed exaggerated reflexes as well as positive Babinski and Rossolimo' sign. Reflexes were intact and within normal range on the straight-leg raise test. Laboratory values at the time of admission are depicted in Table 1.

¹Department of Nephrology, General Hospital of Tianjin Medical University, Tianjin, China and ²Department of Radiology, General Hospital of Tianjin Medical University, Tianjin, China

Correspondence: Dr Z-F Zheng, Department of Nephrology General Hospital of Tianjin Medical University, No.154 Anshan Road, Heping District, Tianjin 300052, China. E-mail: zhengzhenfeng@vip.126.com

Received 5 March 2015; accepted 7 April 2015; published online 16 June 2015

Gouty tophus in thoracic spine Z-F Zheng et al

Table 1 Laboratory data at presentation

range Blood count 9.05 4.0-10.0 Erythrocytes $(10^{12} ^{-1})$ 3.12 4.0-5.5 Hemoglobin (g d ⁻¹) 90 120-160 Hematocrit (%) 26.4 42.0-49.0 Platelet count $(10^9 ^{-1})$ 26.7 100-300 Serum chemistry	Variable	Result	Reference	
Blood count 9.05 4.0-10.0 Erythrocytes $(10^{12} ^{-1})$ 3.12 4.0-5.5 Hemoglobin (g dl ⁻¹) 90 120-160 Hematocrit (%) 26.4 42.0-49.0 Platelet count $(10^9 ^{-1})$ 247 100-300 Serum chemistry 66 62-85 Albumin (g l ⁻¹) 66 62-85 Globulin (g l ⁻¹) 26.4 35-55 Globulin (g l ⁻¹) 26 26-37 Total cholesterol (mmol l ⁻¹) 2.1 0.57-1.71 Low density lipoprotein (mmol l ⁻¹) 2.152 1.33-3.30 Lactate dehydrogenase (U l ⁻¹) 16 5-40 Glutamic oxaloacetic transaminase (U l ⁻¹) 13 8-40 Blood urea nitrogen (mmol l ⁻¹) 120 44-115 Serum creatinine (µmol l ⁻¹) 120 44-114 Fasting blood glucose (mmol l ⁻¹) 320 140-414 Fasting blood glucose (mmol l ⁻¹) 171 82-453 Immunoglobulin A (mg dl ⁻¹) 171 82-453 Immunoglobulin M (mg dl ⁻¹) 152 79			range	
Leukocytes $(10^{9}1^{-1})$ 9.05 4.0-10.0 Erythrocytes $(10^{12}1^{-1})$ 3.12 4.0-5.5 Hemoglobin (g d ⁻¹) 90 120-160 Hematocrit (%) 26.4 42.0-49.0 Platelet count $(10^{9}1^{-1})$ 267 100-300 Serum chemistry	Blood count			
Erythrocytes $(10^{12} ^{-1})$ 3.12 4.0-5.5 Hemoglobin (g dl ⁻¹) 90 120-160 Hematocrit (%) 26.4 42.0-49.0 Platelet count (10^91^{-1}) 247 100-300 Serum chemistry 40 35-55 Globulin (g l ⁻¹) 40 35-55 Globulin (g l ⁻¹) 4.66 3.59-5.17 Total cholesterol (mmol l ⁻¹) 2.52 1.33-330 Lactate dehydrogenase (U l ⁻¹) 245 94-250 Glutamic oxaloacetic transaminase (U l ⁻¹) 13 8-40 Blood urea nitrogen (mmol l ⁻¹) 7.6 1.7-8.3 Serum creatinine (µmol l ⁻¹) 120 44-115 Serum uric acid (µmol l ⁻¹) 120 44-115 Serum uric acid (µmol l ⁻¹) 120 44-115 Serum uric acid (µmol l ⁻¹) 120 44-1415 Serum uric acid (µmol l ⁻¹) 171 82-453 Immunoglobulin G (mg dl ⁻¹) 171 82-453 Immunoglobulin M (mg dl ⁻¹) 171 82-453 Immunoglobulin M (mg dl ⁻¹) 152	Leukocytes (10 ⁹ I ⁻¹)	9.05	4.0-10.0	
Hemoglobin (g dl ⁻¹) 90 120-160 Hematocrit (%) 26.4 42.0-49.0 Platelet count (10 ⁹ l ⁻¹) 247 100-300 Serum chemistry 40 35-55 Globulin (g l ⁻¹) 40 35-55 Globulin (g l ⁻¹) 4.66 3.59-5.17 Tatal cholesterol (mmol l ⁻¹) 2.52 1.33-3.30 Lactate dehydrogenase (U l ⁻¹) 2.45 94-250 Glutamic pyruvic transaminase (U l ⁻¹) 16 5-40 Glutamic oxaloacetic transaminase (U l ⁻¹) 13 8-40 Blood urea nitrogen (mmol l ⁻¹) 7.6 1.7-8.3 Serum creatinine (µmol l ⁻¹) 20 140-414 Fasting blood glucose (mmol l ⁻¹) 320 140-414 Fasting blood glucose (mmol l ⁻¹) 320 140-414 Fasting blood glucose (mmol l ⁻¹) 320 140-414 Fasting blood glucose (mmol l ⁻¹) 171 82-453 Immunoglobulin G (mg dl ⁻¹) 171 82-453 Immunoglobulin A (mg dl ⁻¹) 171 82-453 Immunoglobulin G (mg dl ⁻¹) 171 82-453 Immunoglobulin K (mg dl	Erythrocytes $(10^{12} I^{-1})$	3.12	4.0-5.5	
Hematorit (%) 26.4 $42.0-49.0$ Platelet count ($10^9 I^{-1}$) 247 $100-300$ Serum chemistry Total protein ($g I^{-1}$) 66 $62-85$ Albumin ($g I^{-1}$) 40 $35-55$ Globulin ($g I^{-1}$) 2.6 $26-37$ Total cholesterol (mmol I^{-1}) 2.6 $26-37$ Total cholesterol (mmol I^{-1}) 2.52 $1.33-330$ Lactate dehydrogenase (U I^{-1}) 2.45 $94-250$ Glutamic pyruvic transaminase (U I^{-1}) 16 $5-40$ Glutamic pyruvic transaminase (U I^{-1}) 13 $8-40$ Blood urea nitrogen (mmol I^{-1}) 7.6 $1.7-8.3$ Serum creatinine (µmol I^{-1}) 7.6 $1.7-8.3$ Serum creatinine (µmol I^{-1}) 3.0 44-115 Serum creatinine (µmol I^{-1}) 120 $44-115$ 320 $140-414$ Fasting blood glucose (mmol I^{-1}) 120 $44-115$ 320 $140-414$ Fasting blood glucose (mmol I^{-1}) 171 $82-453$ Immunoglobulin A (mg d I^{-1}) 171 $82-453$ Immunoglobulin M (mg dI^{-1}) 171 </td <td>Hemoglobin (g dl⁻¹)</td> <td>90</td> <td>120–160</td>	Hemoglobin (g dl ⁻¹)	90	120–160	
Platelet count $(10^{9} ^{-1})$ 247 100-300 Serum chemistry Total protein (g ⁻¹) 66 62-85 Albumin (g ⁻¹) 40 35-55 Globulin (g ⁻¹) 26 26-37 Total cholesterol (mmol ⁻¹) 4.66 3.59-5.17 Triglyceride (mmol ⁻¹) 2.1 0.57-1.71 Low density lipoprotein (mmol ⁻¹) 2.52 1.33-3.30 Lactate dehydrogenase (U ⁻¹) 16 5-40 Glutamic oxaloacetic transaminase (U ⁻¹) 13 8-40 Blood urea nitrogen (mmol ⁻¹) 7.6 1.7-8.3 Serum creatinine (µmol ⁻¹) 7.6 1.7-8.3 Serum uric acid (µmol ⁻¹) 7.6 1.7-8.3 Serum uric acid (µmol ⁻¹) 120 44-115 Serum uric acid (µmol ⁻¹) 120 44-141 Fasting blood glucose (mmol ⁻¹) 751-1560 1mmunolgoy Immunoglobulin G (mg d ⁻¹) 171 82-453 Immunoglobulin M (mg d ⁻¹) 152 79-152 Complement C3 (mg d ⁻¹) 152 79-152	Hematocrit (%)	26.4	42.0–49.0	
Serum chemistry Total protein (g1 ⁻¹) 66 62–85 Albumin (g1 ⁻¹) 40 35–55 Globulin (g1 ⁻¹) 26 26–37 Total cholesterol (mmol1 ⁻¹) 2.1 0.57–1.71 Low density lipoprotein (mmol1 ⁻¹) 2.52 1.33–3.30 Lactate dehydrogenase (U1 ⁻¹) 2.45 94–250 Glutamic pyruvic transaminase (U1 ⁻¹) 16 5–40 Glutamic oxaloacetic transaminase (U1 ⁻¹) 13 8–40 Blood urea nitrogen (mmol1 ⁻¹) 7.6 1.7–8.3 Serum creatinine (µmol1 ⁻¹) 7.6 1.7–8.3 Serum creatinine (µmol1 ⁻¹) 7.6 1.7–8.3 Serum uric acid (µmol1 ⁻¹) 7.6 1.7–8.3 Serum uric acid (µmol1 ⁻¹) 7.6 1.7–8.3 Serum uric acid (µmol1 ⁻¹) 7.6 1.7–8.3 Immunolgoy Immunoglobulin G (mg d1 ⁻¹) 120 44–115 Immunoglobulin G (mg d1 ⁻¹) 171 82–453 Immunoglobulin M (mg d1 ⁻¹) 171 82–453 Immunoglobulin M (mg d1 ⁻¹) 171 82–45	Platelet count (10 ⁹ l ⁻¹)	247	100-300	
Total protein (g1 ⁻¹) 66 62-85 Albumin (g1 ⁻¹) 40 35-55 Globulin (g1 ⁻¹) 26 26-37 Total cholesterol (mmol 1 ⁻¹) 2.1 0.57-1.71 Low density lipoprotein (mmol 1 ⁻¹) 2.52 1.33-3.30 Lactate dehydrogenase (U1 ⁻¹) 245 94-250 Glutamic pyruvic transaminase (U1 ⁻¹) 16 5-40 Glutamic oxaloacetic transaminase (U1 ⁻¹) 13 8-40 Blood urea nitrogen (mmol 1 ⁻¹) 7.6 1.7-8.3 Serum creatinine (µmol 1 ⁻¹) 7.6 1.7-8.3 Serum uric acid (µmol 1 ⁻¹) 320 140-414 Fasting blood glucose (mmol 1 ⁻¹) 6.2 3.6-5.8 Immunoglobulin G (mg d1 ⁻¹) 171 82-453 Immunoglobulin A (mg d1 ⁻¹) 171 82-453 Immunoglobulin M (mg d1 ⁻¹) 152 79-152 Complement C3 (mg d1 ⁻¹) 152 79-152 Complement C4 (mg d1 ⁻¹) 3.2 <13	Serum chemistry			
Albumin (g l ⁻¹) 40 $35-55$ Globulin (g l ⁻¹) 26 $26-37$ Total cholesterol (mmol l ⁻¹) 4.66 $3.59-5.17$ Triglyceride (mmol l ⁻¹) 2.1 $0.57-1.71$ Low density lipoprotein (mmol l ⁻¹) 2.45 $94-250$ Glutamic pyruvic transaminase (U l ⁻¹) 16 $5-40$ Glutamic coxaloacetic transaminase (U l ⁻¹) 13 $8-40$ Blood urea nitrogen (mmol l ⁻¹) 7.6 $1.7-8.3$ Serum creatinine (µmol l ⁻¹) 7.6 $1.7-8.3$ Serum uric acid (µmol l ⁻¹) 320 $140-414$ Fasting blood glucose (mmol l ⁻¹) 320 $140-414$ Fasting blood glucose (mmol l ⁻¹) 6.2 $3.6-5.8$ <i>Immunolgoy</i> Immunoglobulin G (mg dl ⁻¹) 171 $82-453$ Immunoglobulin A (mg dl ⁻¹) 171 $82-453$ Immunoglobulin E (IU ml ⁻¹) Immunoglobulin K (mg dl ⁻¹) 152 $79-152$ Complement C3 (mg dl ⁻¹) 38 $16-38$ C-reactive protein (mg dl ⁻¹) 3.2 <13 Antinuclear antibodies Negative Negative Antibody against double-stranded DNA	Total protein (g I ⁻¹)	66	62–85	
Globulin (g I ⁻¹) 26 26-37 Total cholesterol (mmol I ⁻¹) 4.66 3.59-5.17 Triglyceride (mmol I ⁻¹) 2.1 0.57-1.71 Low density lipoprotein (mmol I ⁻¹) 2.52 1.33-3.30 Lactate dehydrogenase (U I ⁻¹) 245 94-250 Glutamic pyruvic transaminase (U I ⁻¹) 16 5-40 Glutamic oxaloacetic transaminase (U I ⁻¹) 13 8-40 Blood urea nitrogen (mmol I ⁻¹) 7.6 1.7-8.3 Serum creatinine (µmol I ⁻¹) 120 44-115 Serum uric acid (µmol I ⁻¹) 320 140-414 Fasting blood glucose (mmol I ⁻¹) 320 140-414 Fasting blood glucose (mmol I ⁻¹) 320 140-414 Fasting blood glucose (mmol I ⁻¹) 171 82-453 Immunoglobulin G (mg dI ⁻¹) 171 82-453 Immunoglobulin M (mg dI ⁻¹) 152 79-152 Complement C3 (mg dI ⁻¹) 152 79-152 Complement C4 (mg dI ⁻¹) 3.2 <13	Albumin (gl ⁻¹)	40	35–55	
Total cholesterol (mmol I^-1)4.66 $3.59-5.17$ Triglyceride (mmol I^-1) 2.1 $0.57-1.71$ Low density lipoprotein (mmol I^-1) 2.52 $1.33-3.30$ Lactate dehydrogenase (U I^-1) 245 $94-250$ Glutamic pyruvic transaminase (U I^-1) 16 $5-40$ Glutamic oxaloacetic transaminase (U I^-1) 13 $8-40$ Blood urea nitrogen (mmol I^-1) 7.6 $1.7-8.3$ Serum creatinine (µmol I^-1) 320 $140-414$ Fasting blood glucose (mmol I^-1) 320 $140-414$ Fasting blood glucose (mmol I^-1) 320 $140-414$ Fasting blood glucose (mmol I^-1) $751-1560$ ImmunolgoyImmunoglobulin G (mg dI^-1) 171 Immunoglobulin M (mg dI^-1) 116 <165 Complement C3 (mg dI^-1) 152 $79-152$ Complement C4 (mg dI^-1) 38 $16-38$ C-reactive protein (mg dI^-1) 3.2 <13 Antinuclear antibodiesNegativeNegativeAntibodies to extractable nuclear antigensNegativeNegativeAnti-eutrophil cytoplasmic antibodiesNegativeNegativeAnti-eglomerular basement membranous <20 <20 antibody (RU mI^-1) 1.3 <2.0 Anti-ribosomal P-protein antibodyNegativeAnti-cyclic citndlinated peptide antibody (U mI^-1) 5.2 Anti-eratin antibodyNegativeAnti-eratin antibodyNegativeAnti-eratin antibodyNegativeAnti-eratin antibodyNegative	Globulin (gl ⁻¹)	26	26–37	
Triglyceride (mmol I ⁻¹) 2.1 $0.57-1.71$ Low density lipoprotein (mmol I ⁻¹) 2.52 $1.33-3.30$ Lactate dehydrogenase (U I ⁻¹) 245 $94-250$ Glutamic pyruvic transaminase (U I ⁻¹) 16 $5-40$ Blood urea nitrogen (mmol I ⁻¹) 13 $8-40$ Blood urea nitrogen (mmol I ⁻¹) 7.6 $1.7-8.3$ Serum creatinine (µmol I ⁻¹) 7.6 $1.7-8.3$ Serum uric acid (µmol I ⁻¹) 320 $140-414$ Fasting blood glucose (mmol I ⁻¹) 6.2 $3.6-5.8$ Immunoglobulin G (mg dI ⁻¹) 991 $751-1560$ Immunoglobulin M (mg dI ⁻¹) 171 $82-453$ Immunoglobulin M (mg dI ⁻¹) 176 <165 Complement C3 (mg dI ⁻¹) 152 $79-152$ Complement C4 (mg dI ⁻¹) 152 $79-152$ Complement C4 (mg dI ⁻¹) 3.2 <13 Antinuclear antibodies Negative Negative Antinuclear antibodies Negative Negative Antinuclear antibodies Negative Negative Antinuclear antibody Negative Negative <td>Total cholesterol (mmol I⁻¹)</td> <td>4.66</td> <td>3.59–5.17</td>	Total cholesterol (mmol I ⁻¹)	4.66	3.59–5.17	
Low density lipoprotein (mmol I^1)2.521.33-3.30Lactate dehydrogenase (U I^1)24594-250Glutamic pyruvic transaminase (U I^1)165-40Glutamic oxaloacetic transaminase (U I^1)138-40Blood urea nitrogen (mmol I^1)7.61.7-8.3Serum creatinine (µmol I^1)12044-115Serum uric acid (µmol I^1)320140-414Fasting blood glucose (mmol I^1)6.23.6-5.8ImmunologyImmunoglobulin G (mg dI^1)17182-453Immunoglobulin M (mg dI^1)17182-453Immunoglobulin E (IU mI^1)16<165	Triglyceride (mmol I ⁻¹)	2.1	0.57-1.71	
Lactate dehydrogenase (U I $^{-1}$)24594-250Glutamic pyruvic transaminase (U I $^{-1}$)165-40Glutamic oxaloacetic transaminase (U I $^{-1}$)138-40Blood urea nitrogen (mmol I $^{-1}$)7.61.7-8.3Serum creatinine (µmol I $^{-1}$)12044-115Serum uric acid (µmol I $^{-1}$)320140-414Fasting blood glucose (mmol I $^{-1}$)6.23.6-5.8ImmunologyImmunoglobulin G (mg dI $^{-1}$)17182-453Immunoglobulin M (mg dI $^{-1}$)17182-453Immunoglobulin M (mg dI $^{-1}$)116<165	Low density lipoprotein (mmol I ⁻¹)	2.52	1.33–3.30	
Glutamic pyruvic transaminase (U I $^{-1}$)165-40Glutamic oxaloacetic transaminase (U I $^{-1}$)138-40Blood urea nitrogen (mmol I $^{-1}$)7.61.7-8.3Serum creatinine (µmol I $^{-1}$)12044-115Serum uric acid (µmol I $^{-1}$)320140-414Fasting blood glucose (mmol I $^{-1}$)6.23.6-5.8Immunoglobulin G (mg dI $^{-1}$)17182-453Immunoglobulin M (mg dI $^{-1}$)17182-453Immunoglobulin K (mg dI $^{-1}$)116<165	Lactate dehydrogenase (UI ⁻¹)	245	94–250	
Glutamic oxaloacetic transaminase (U1^1)138-40Blood urea nitrogen (mmol1^1)7.61.7-8.3Serum creatinine (µmol1^1)12044-115Serum uric acid (µmol1^1)320140-414Fasting blood glucose (mmol1^1)6.23.6-5.8ImmunologyImmunoglobulin G (mg d1^1)991751-1560Immunoglobulin A (mg d1^1)17182-453Immunoglobulin K (mg d1^1)17182-453Immunoglobulin E (IU m1^1)116<165	Glutamic pyruvic transaminase (UI ⁻¹)	16	5–40	
Blood urea nitrogen (mmol I^-1)7.61.7–8.3Serum creatinine (µmol I^-1)12044–115Serum uric acid (µmol I^-1)320140–414Fasting blood glucose (mmol I^-1)6.23.6–5.8ImmunologyImmunoglobulin G (mg dI^-1)17182–453Immunoglobulin M (mg dI^-1)17182–453Immunoglobulin K (mg dI^-1)17182–453Immunoglobulin K (mg dI^-1)116<165	Glutamic oxaloacetic transaminase (UI ⁻¹)	13	8–40	
Serum creatinine (µmol I^-1)12044–115Serum uric acid (µmol I^-1)320140–414Fasting blood glucose (mmol I^-1)6.23.6–5.8ImmunologyImmunoglobulin G (mg dl^-1)991751–1560Immunoglobulin A (mg dl^-1)17182–453Immunoglobulin M (mg dl^-1)4746–304Immunoglobulin E (IU ml^-1)116<165	Blood urea nitrogen (mmol I ⁻¹)	7.6	1.7-8.3	
Serum uric acid (µmol -1) 320 $140-414$ Fasting blood glucose (mmol -1) 6.2 $3.6-5.8$ ImmunologyImmunoglobulin G (mg dl ⁻¹) 991 $751-1560$ Immunoglobulin A (mg dl ⁻¹) 171 $82-453$ Immunoglobulin M (mg dl ⁻¹) 171 $82-453$ Immunoglobulin E (IU ml ⁻¹) 116 <165 Complement C3 (mg dl ⁻¹) 152 $79-152$ Complement C4 (mg dl ⁻¹) 152 $79-152$ Complement C4 (mg dl ⁻¹) 38 $16-38$ C-reactive protein (mg dl ⁻¹) 3.2 <13 Antinuclear antibodiesNegativeNegativeAntinuclear antibodiesNegativeNegativeAnti-neutrophil cytoplasmic antibodiesNegativeNegativeAnti-cardiolipin antibodyNegativeNegativeAnti-cardiolipin antibodyNegativeNegativeAnti-cyclic citndlinated peptide antibody (U ml ⁻¹) 6.4 <12.0 Anti-RA33 antibody (U ml ⁻¹) 11.3 <25.0 Anti-keratin antibodyNegativeNegativeAnti-keratin antibodyNegativeNegativeAnti-keratin antibodyNegativeNegativeAnti-reducting interve of the order of the	Serum creatinine (µmol I ⁻¹)	120	44–115	
Fasting blood glucose (mmol I $^{-1}$)6.23.6–5.8ImmunologyImmunoglobulin G (mg dl $^{-1}$)991751–1560Immunoglobulin A (mg dl $^{-1}$)17182–453Immunoglobulin M (mg dl $^{-1}$)17182–453Immunoglobulin E (IU ml $^{-1}$)116<165	Serum uric acid (µmol I ⁻¹)	320	140-414	
ImmunologyImmunoglobulin G (mg dl^1)991751–1560Immunoglobulin A (mg dl^1)17182–453Immunoglobulin M (mg dl^1)4746–304Immunoglobulin E (IU ml^1)116<165	Fasting blood glucose (mmol I^{-1})	6.2	3.6–5.8	
Immunoglobulin G (mg dl^1)991751-1560Immunoglobulin A (mg dl^1)17182-453Immunoglobulin M (mg dl^1)4746-304Immunoglobulin E (IU ml^1)116<165	Immunology			
Immunoglobulin A (mg dl^1)171 $82-453$ Immunoglobulin M (mg dl^1)47 $46-304$ Immunoglobulin E (IU ml^1)116<165	Immunoglobulin G (mg dl ⁻¹)	991	751–1560	
Immunoglobulin M (mg dl^1)4746-304Immunoglobulin E (IU ml^1)116<165	Immunoglobulin A (mgdl ⁻¹)	171	82–453	
Immunoglobulin E (IU mI^1)116<165Complement C3 (mg dI^1)15279-152Complement C4 (mg dI^1)3816-38C-reactive protein (mg dI^1)12.9<0.8	Immunoglobulin M (mg dl ⁻¹)	47	46–304	
Complement C3 (mg dl^1)15279-152Complement C4 (mg dl^1)3816-38C-reactive protein (mg dl^1)12.9<0.8	Immunoglobulin E (IU ml ⁻¹)	116	<165	
Complement C4 (mg dl^1)3816-38C-reactive protein (mg dl^1)12.9<0.8	Complement C3 (mg dl $^{-1}$)	152	79-152	
C-reactive protein (mg dl^-1)12.9<0.8Circulating immune complexes (U ml^-1)3.2<13	Complement C4 (mg dl $^{-1}$)	38	16-38	
Circulating immune complexes (U ml^-1) 3.2 <13Antinuclear antibodiesNegativeNegativeAntibody against double-stranded DNANegativeNegativeAntibodies to extractable nuclear antigensNegativeNegativeAnti-neutrophil cytoplasmic antibodiesNegativeNegativeAnti-glomerular basement membranous<20	C-reactive protein (mg dI $^{-1}$)	12.9	< 0.8	
Antinuclear antibodiesNegativeNegativeAntibody against double-stranded DNANegativeNegativeAntibodies to extractable nuclear antigensNegativeNegativeAnti-neutrophil cytoplasmic antibodiesNegativeNegativeAnti-glomerular basement membranous<20	Circulating immune complexes (U ml ⁻¹)	3.2	<13	
Antibody against double-stranded DNANegativeNegativeAntibodies to extractable nuclear antigensNegativeNegativeAnti-neutrophil cytoplasmic antibodiesNegativeNegativeAnti-glomerular basement membranous <20 <20 antibody (RU ml ⁻¹)NegativeNegativeAnti-cardiolipin antibodyNegativeNegativeAnti-ribosomal P-protein antibodyNegativeNegativeSerum immunofixation electrophoresisNegativeNegativeAnti-cyclic citndlinated peptide antibody (U ml ⁻¹) 6.4 <12.0 Anti-RA33 antibody (U ml ⁻¹) 11.3 <25.0 Anti-keratin antibodyNegativeNegativeAnti-perinuclear factor antibodyNegativeNegativeRheumatoid factor IgA subclass (U ml ⁻¹) 8.8 <12.0 Rheumatoid factor IgG subclass (U ml ⁻¹) 10.3 <12.0	Antinuclear antibodies	Negative	Negative	
Antibodies to extractable nuclear antigensNegativeNegativeAnti-neutrophil cytoplasmic antibodiesNegativeNegativeAnti-glomerular basement membranous <20 <20 antibody (RU ml ⁻¹)NegativeNegativeAnti-cardiolipin antibodyNegativeNegativeAnti-ribosomal P-protein antibodyNegativeNegativeSerum immunofixation electrophoresisNegativeNegativeAnti-cyclic citndlinated peptide antibody (U ml ⁻¹) 6.4 <12.0 Anti-mutated citrullinated vimentin antibody (U ml ⁻¹) 5.2 <20.0 Anti-keratin antibodyNegativeNegativeAnti-keratin antibodyNegativeNegativeAnti-perinuclear factor antibodyNegativeNegativeRheumatoid factor IgA subclass (U ml ⁻¹) 8.8 <12.0 Rheumatoid factor IgG subclass (U ml ⁻¹) 10.3 <12.0	Antibody against double-stranded DNA	Negative	Negative	
Anti-neutrophil cytoplasmic antibodiesNegativeNegativeAnti-glomerular basement membranous < 20 < 20 antibody (RU ml ⁻¹)NegativeNegativeAnti-cardiolipin antibodyNegativeNegativeAnti-ribosomal P-protein antibodyNegativeNegativeSerum immunofixation electrophoresisNegativeNegativeAnti-cyclic citndlinated peptide antibody (U ml ⁻¹) 6.4 < 12.0 Anti-mutated citrullinated vimentin antibody (U ml ⁻¹) 5.2 < 20.0 Anti-RA33 antibody (U ml ⁻¹) 11.3 < 25.0 Anti-keratin antibodyNegativeNegativeAnti-perinuclear factor antibodyNegativeNegativeRheumatoid factor IgA subclass (U ml ⁻¹) 8.8 < 12.0 Rheumatoid factor IgG subclass (U ml ⁻¹) 10.3 < 12.0	Antibodies to extractable nuclear antigens	Negative	Negative	
Anti-glomerular basement membranous<20<20antibody (RU ml^-1)NegativeNegativeAnti-cardiolipin antibodyNegativeNegativeAnti-ribosomal P-protein antibodyNegativeNegativeSerum immunofixation electrophoresisNegativeNegativeAnti-cyclic citndlinated peptide antibody (U ml^-1)6.4<12.0	Anti-neutrophil cytoplasmic antibodies	Negative	Negative	
Anti-cardiolipin antibodyNegativeNegativeAnti-cardiolipin antibodyNegativeNegativeAnti-ribosomal P-protein antibodyNegativeNegativeSerum immunofixation electrophoresisNegativeNegativeAnti-cyclic citrullinated peptide antibody (U ml ⁻¹) 6.4 <12.0	Anti-glomerular basement membranous	<20	<20	
Anti-calconput diffectlyNegativeNegativeAnti-ribosomal P-protein antibodyNegativeNegativeSerum immunofixation electrophoresisNegativeNegativeAnti-cyclic citrullinated peptide antibody (U ml ⁻¹) 6.4 <12.0	Anti-cardiolinin antibody	Negative	Negative	
Nint incoding in potent antibodyNegativeNegativeSerum immunofixation electrophoresisNegativeNegativeAnti-cyclic citndlinated peptide antibody (U ml ⁻¹) 6.4 <12.0	Anti-ribosomal P-protein antibody	Negative	Negative	
Anti-cyclic citndlinated peptide antibody $(U ml^{-1})$ 6.4 <12.0Anti-nutated citrullinated vimentin antibody $(U ml^{-1})$ 5.2 <20.0	Serum immunofization electrophoresis	Negative	Negative	
Anti-mutated citrullinated vimentin antibody (U ml $^{-1}$)5.2<20.0Anti-RA33 antibody (U ml $^{-1}$)11.3<25.0	Anti-cyclic citralinated pentide antibody $(m ^{-1})$	6.4	< 12.0	
Anti-RA33 antibody (U ml ⁻¹) 11.3 <25.0	Anti-mutated citrullinated vimentin antibody ($U m l^{-1}$)	5.2	< 20.0	
Anti-keratin antibody Negative Negative Anti-perinuclear factor antibody Negative Negative Rheumatoid factor IgA subclass (U ml ⁻¹) 8.8 <12.0	Anti-RA33 antibody $(U m l^{-1})$	11.3	< 25.0	
Anti-perinuclear factor antibody Negative Negative Rheumatoid factor IgA subclass (U mI ⁻¹) 8.8 <12.0	Anti-keratin antibody	Negative	Negative	
Rheumatoid factor IgA subclass (U mI $^{-1}$)8.8<12.0Rheumatoid factor IgG subclass (U mI $^{-1}$)10.3<12.0	Anti-perinuclear factor antibody	Negative	Negative	
Rheumatoid factor IgG subclass (U ml ⁻¹) $10.3 < 12.0$	Rheumatoid factor IgA subclass ($IImI^{-1}$)	8.8	< 12.0	
	Rheumatoid factor IgG subclass (U ml ⁻¹)	10.3	<12.0	

The bold and italic entries indicate abnormal values beyond the reference range.

Computed tomography of the thoracic spine showed spinal stenosis at the T3/T4, T9-T12 levels. He also underwent magnetic resonance imaging, which showed hypertrophic ligamentum flavum at the level of T3/T4, T5/T6, T9/T10, T10/T11 and T11/T12 (Figures 1 and 2). The discs of T7/T8, L3/L4, and L5/S1 showed posterior bulge. Degenerative disc disease was found at the levels of T1/T2, T12/L1, L1/L2 and L5/S1.

A thoracic laminectomy was performed at T1-T5. During the operation, an abnormal mass with a white, chalky, cheese-like and

granular appearance was observed. A culture of the chalky material revealed no bacterial growth. A histological examination of the material removed during the laminectomy showed amorphous eosinophilic material with thin needle-shaped crystals that were negatively birefringent on polarizing microscopy. Bacteriologic examinations were negative.

After his operation, his back pain and skin anesthesia of the lower extremities was markedly improved. He was prescribed allopurinol and transferred to a rehabilitation facility.

DISCUSSION

The first radiologic and pathologic description of gouty involvement of the spine was published by Kersley et al. in 1950.10 However, the first case of thoracic gouty spine patient was not discussed until the report by Koskoff et al. in 1953.11 To the best of our knowledge, 21 thoracic spine cases have been reported. The reported cases of spinal gout involvement of thoracic vertebrae are listed in Table 2.7,11-30 There was significant gender difference with a male-to-female ratio of 17:4 in the reported cases. Fourteen (66.7%) patients reported a history of gout symptom ranging from 2 to 35 years.^{11-13,15-20,22-25,30} Peripheral tophi were found in ten (47.6%) patients.^{7,11–13,15–19,25} Although tophi were reported in all thoracic regions, the most frequent involvement was seen in the thoracic region at T7-T10 (Figure 3). The most common location of gouty tophi involvement was extradural space.^{11,13–16,18,21,22,25,26} Other locations of axial elements, such as facet joints,^{23,29,30} discs,¹² vertebral bodies,^{7,12,17,19,20} pedicles^{7,13,27,30} and costovertebral joint²⁸ have been reported. However, the formation of gouty tophi within the thoracic spine involving the ligamentum flavum causing spinal cord compression, as occurs in our case, have only been reported previously by Wang et al.²³ and Hus et al.24

The prevalence of spinal gout is unclear since most of the available information comes from anecdotal case-reports. Konatalapalli *et al.*³¹ reviewed 630 patients who were diagnosed with gouty arthritis, tophaceous gout or unspecified gout. Sixty-four patients had computed tomography images of cervical, thoracic or pelvic region. Spinal gout was identified in 9 of these 64 patients (14%). More recently, Konatalapalli *et al.* accomplished a cross-sectional study regarding axial gout. Seventeen of the 48 subjects (35%) had computed tomography evidence of spinal gout and 7 (15%) had spinal tophi.³² On the basis of these observational studies, we speculated that the prevalence of axial gouty tophi was grossly underestimated.

Although the etiopathogenesis of the crystal accumulation in the axial skeleton is not completely known, it has been reported that factors such as degenerative disease of the spine, necrosis of the tissues or previous injuries can trigger the process.^{4,33,34} Meanwhile, some predisposing factors such as old age, low temperature, low serum pH level, renal insufficiency, diuretic and cyclospine A agent, IgA nephropathy and high alcohol intake are thought to promote tophi formation and development. The reason for the involvement of peripheral joints in gout is considered to be related to the decrease of the solubility of the crystals in the places with lower temperature and formation of tophi in avascular tissues.^{4,35} In addition, lower blood pH causes a decrease in the binding plasma proteins and trauma causes an increase in the precipitation of urate crystals, both of which cause an increase in tophus formation.^{4,35,36} In our review, most of the patients with gouty tophi involved T7 through T10, which was consistent with the possibility that inflammation associated with motion-related damage may create an environment favorable for urate deposition. Renal dysfunction plays a significant role in raising the uric acid levels of the serum. Primary or secondary renal function



Figure 1 Sagittal image of hypointensity magnetic resonance imaging shows hypertrophy ligamentum flavum. (a) T1-weighted image shows the lesion at the T3-T4 level. (b) T1-weighted image shows the lesions at the T9-T10, T10-T11 and T11-T12 levels. (c) T2-weighted image shows the lesion at the T3-T4 level. (d) T2-weighted image shows the lesions at the T9-T10, T10-T11 and T11-T12 levels.



Figure 2 Axial images of hypointensity magnetic resonance imaging shows hypertrophy of the ligamentum flavum on T2-weighted image. (a) The lesion at the T3-T4 level. (b) The lesion at the T9-T10 level. (c) The lesion at the T10-T11 level. (d) The lesion at the T11-T12 level.

ans of Treatment Evaluation gnosis	eration Decompression Improved iopsy ND NA	eration Laminectomy Improved eration NR NR	eration Laminectomy Improved eration Laminectomy Improved	edle Laminectomy Improved psy Improved eration Laminectomy Improved	edle Conservative Improved psy eration Laminectomy NR	eration Laminectomy Improved sration Laminectomy Improved	eration Laminectomy Resovled	eration Laminectomy NR eration Laminectomy Resovled	eration Laminectomy Improved	eration Laminectomy Resovled edle Conservative Improved	edle Conservative Decreased psy NR NR	eration Laminectomy Improved
Location of Me t involvement dia	Extradural Op space Disc; vertebral Au	bodies Extradural Op space; pedicles Extradural Op	Extradural Op space Extradural Op	Vertebral bodies bio Extradural Op	Vertebral Ne bodies bio Vertebral Op bodies	Extradural Op space Extradural Op	space Facet joint; Op ligamentum	Ligamentum Op flavum Extradural Op	space Extradural Op space	Pedicles Op Pedicles; ver- Ne tobrol hodiac his	Costovertebral Ne joint biot	Facet joint; Op pedicles
Level of involvemen	Т9-Т11 Т12-L1	Т7-Т11 Т1	T6-T7 T4-T9	T8-T9 T2-T9	Т4;Т7 Т8	T10-T11 T1-T2	T9-T10	T9-T11 T9-T10	T7-T9	T4-T7 T8;T10	T9;T10; T12 T10_T11	T6-T7
Serum uric acid level (µmol I ⁻¹)	625 774	560 NR	619 929	NR 340	726 NA	506 NR	601	375 NR	620	571 NR	462 NR	726
Clinical description of gout	Severe, polyarticular, tophi Severe, polyarticular,	topni Severe, polyarticular, NR	Mild, Polyarticular tophi Severe, polyarticular, tophi	Severe, polyarticular, tophi Severe, polyarticular, tobhi	Polyarticular, tophi Polyarticular, no tophi	Polyarticular, no tophi No tophi	Polyarticular, no tophi	No tophi Severe, polyarticular,	tophi No tophi	No tophi Severe, polyarticular,	No tophi NP	NR
Neurological symptoms	Bilateral legs paralysis: back aching pain; bilateral lower extremities weakness Normal	Midthoracic pain; bilateral lower limbs paralysis and weakness; urinary retention Bilateral legs paralysis; gait disturbance	Back pain, hypesthesia; bilateral lower extremites weakness Bilateral lower extremites paralysis and weakness	Back pain; uninary retention; unilaterial right leg weakness Bilateral lower extremities paralysis and weakness	Back pain; Back pain; Bowel and bladder dysfunction; bilateral lower extremites weakness;	Blaten pain Blaten Jower extremites weakness; urinary retention Unilateral left leg weakness	Back pain; bilateral lower extremities paralysis; urinary retention	Bilateral lower extremites weakness and numbness Back pain; unilateral right leg	weakness, sensory impairment Back pain	Bilateral lower extremites weakness; sensory impaired Bilateral lower extremites weakness	Back pain Back pain, bilateral lower actromities	weakness weakness weakness iteable.
History of gout symptom (years)	12 35	NR 5	17 Q	25 16	ω 4	5 10	വ	2 2	NA	NA NA	NN AN	NA. not app
Gender	ΣΣ	ΣΣ	ΣΣ	шш	ΣĿ	ΣΣ	Σ	ΣΣ	Σ	μΣ	ΣZ	D. not done:
Age (years)	44 56	33 73	60 56	53 59	59	82 60	28	83 49	32	36 76	25	64 Frebort: N
Country	United States United	States Australia United Kingdom	Japan France	United State France	United State South Africa	Taiwan United	Kingdom Taiwan	Taiwan Brazil	United States	United States Hong	Canada	States Korea male: NR. not
Publication year	1953 1956	1983 1987	1994 1997	1998 1999	1999 1999	2000 2001	2001	2002 2002	2004	2006 2009	2013	2013 2013 F. female: M.
Author	Koskoff <i>et al.</i> Levin	et al. Leaney et al. Downey	Yasuhara <i>et al.</i> Dhote	Pfister <i>et al.</i> Bret <i>et al.</i>	Hausch <i>et al.</i> Kaye <i>et al.</i>	Kao <i>et al.</i> St George	et al. Wang et al.	Hsu <i>et al.</i> Souza	<i>et al.</i> El Sandid <i>et al.</i>	Popovich <i>et al.</i> Chan	et al. Kwan et al. Nassori	et al. Abbreviations:

Table 2 Demographic and clinical characteristics of patients with tophaceous gout of the spine

Spinal Cord

npg 884



Figure 3 Distribution characteristics of reported tophaceous gout of the thoracic spine in the literature. (a) Distribution of the patient's age. (b) Distribution of the involved location.

promotes uric acid levels, causing tophi deposition in the spine and mild spinal stenosis with abnormal nerve compression. In turn, the elevated serum acid level further impairs renal function and contributes to the worsening of tophi deposition, which is supported by Chonchol *et al.*³⁷ Our patient had a long history of hyperurecimia, with only intermittent pharmaceutical control. Subcutaneous deposition of gouty tophi in the right elbow area was also noted at this time. Thus, a relatively low environmental temperature and decreased renal urate clearance may be prerequisites for urate deposition.

Clinical manifestations of thoracic spinal gout range from back pain, unilateral or bilateral extremities paralysis, limbs weakness, sensory impaired to urinary retention. Neurologic symptoms were dependent on the level of the spine that was affected.

On MR, spinal tophi appear as homogeneous areas of intermediateto-low signal intensity on T1-weighted images. On T2-weighted images, the signal intensity of the tophi varies from homogeneous hyperintensity to homogeneous hypointensity. This hyperintensity may result from a relative increase in the water content of the tophus and the relative homogeneity of local magnetic field within the tophi. In comparison, the T2-weighted hypointensity may be caused by immobile protons in the tophi. This appearance can be due to regions of calcifications, mature fibrous tissue, or hemosiderin deposition in the tophi. After gadolinium enhancement, the tophi show homogeneous or heterogeneous marginal enhancement. The enhancement of the tophi is thought to be the result of well-vascularized chronic, inflammatory fibrous tissue engendered by urate crystal deposition.^{4,24}

Gouty tophi are nodular, chalky white in the center, made of monosodium urate crystals, proteins, and mucopolysaccharides. Under microscopy, the urate depositions are found to be surrounded by multinucleated histiocytes, which are giant cells with foreign bodies associated with lymphoplasmocytic cells and fibroblasts. Moreover, monosodium urate crystals can be dissolved by formalin. This may be a reason why in our case there were no birefringent crystals under polarized light. It is important that the specimen should be properly fixed after biopsy or operation.

Surgical decompression such as laminectomy followed by optimization of pharmacological treatment can improve the patient's clinical symptoms and provide a good prognosis. Modification of risk factors such as alcohol consumption, improvement in renal function, or alteration of the diuretic regimen may be beneficial and should be pursued whenever possible. Frequent follow-ups and imaging studies may permit early diagnosis and minimized complications of this disease.

CONCLUSION

In conclusion, although spinal gout maybe rare, it is important to be aware of this possibility. The clinician should include spinal gout as a differential diagnosis when dealing with patients with gout and axial pain with or without neurologic deficits. Even a short, uncontrolled period of time in the course of the disease could lead to devastating neurologic deficits necessitating emergent surgery for decompression. If this diagnosis is seriously entertained, then a computed tomography scan or magnetic resonance imaging as well as tissue biopsy may be needed to establish the diagnosis. If gout is suspected at the time of the biopsy, this needs to be communicated to the pathologist because monosodium urate crystals will dissolve during routine histologic processing.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Dr Fangtan Li for providing magnetic resonance imaging figures.

Author contributions: Z-F Zheng and Y Xing are responsible for patient clinical diagnosis and therapy. They also collected patient follow-up data and drafted the manuscript. H-L Shi collected the radiological data and provided interpretation. D Li and J-Y Jia reviewed the literature and summarized the data. S Lin prepared the final version of the manuscript. All authors read and approved the final manuscript.

- Doherty M. New insights into the epidemiology of gout. *Rheumatology (Oxford)* 2009; 48: ii2-ii8.
- 2 Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 1967; 42: 27–37.
- 3 Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. *J Rheumatol* 2004: **31**: 1582–1587.
- 4 King JC, Nicholas C. Gouty arthropathy of the lumbar spine: a case report and review of the literature. Spine (Phila Pa 1976) 1997; 22: 2309–2312.
- 5 Hasturk AE, Basmaci M, Canbay S, Vural C, Erten F. Spinal gout tophus: a very rare cause of radiculopathy. *Eur Spine J* 2012; 21: S400–S403.
- 6 Dharmadhikari R, Dildey P, Hide IG. A rare cause of spinal cord compression: imaging appearances of gout of the cervical spine. Skeletal Radiol 2006; 35: 942–945.
- 7 Chan AT, Leung JL, Sy AN, Wong WW, Lau KY, Ngai WT et al. Thoracic spinal gout mimicking metastasis. Hong Kong Med J 2009; 15: 143–145.
- 8 Cabot J, Mosel L, Kong A, Hayward M. Tophaceous gout in the cervical spine. Skeletal Radiol 2005; 34: 803–806.
- 9 Sanmillan Blasco JL, Vidal Sarro N, Marnov A, Acebes Martin JJ. Cervical cord compression due to intradiscal gouty tophus. *Spine (Phila Pa 1976)* 2012; **37**: E1534–E1536.

- 10 Kersley GD, Mandel L, Jeffrey MR. Gout, an unusual case with softening and subluxation of the first cervical vertebra and splenomegaly: result of ACTH administration and eventual post-mortem findings. Ann Rheumat Dis 1950; 9: 282–303.
- 11 Koskoff YD, Morris LE, Lubic LG. Paraplegia as a complication of gout. JAMA 1953; 152: 37–38.
- 12 Levin MH, Linchtenstein L, Scott HW. Pathologic changes in gout: survey of eleven necropsied cases. Am J Pathol 1956; 32: 871–895.
- 13 Leaney BJ, Calvert JM. Tophaceous gout producing spinal cord compression. *J Neurosurg* 1983; **58**: 580–582.
- 14 Downey PR, Brophy BP, Sage MR. Four unusual cases of spinal cord compression. Australas Radiol 1987; 31: 136–141.
- 15 Yasuhara K, Tomita Y, Takayama A, Fujikawa H, Otake Y, Takahashi K. Thoracic myelopathy due to compression by the epidural tophus: A case report. J Spinal Disord 1994; 7: 82–85.
- 16 Dhôte R, Roux FX, Bachmeyer C, Tudoret L, Daumas-Duport C, Christoforov B. Extradural spinal tophaceous gout: evolution with medical treatment. *Clin Exp Rheumatol* 1997; **15**: 421–423.
- 17 Pfister AK, Schlarb CA, O'Neal JF. Vertebral erosion, paraplegia and spinal gout. AJR Am J Roentgenol 1998; 171: 1430–1431.
- 18 Bret P, Ricci AC, Saint-Pierre G, Mottolese C, Guyotat J. Thoracic spinal cord compression by a gouty tophus. Case report. Review of the literature. *Neurochirurgie* 1999; **45**: 402–406.
- 19 Hausch R, Wilkerson M, Singh E, Reyes C, Harrington T. Tophaceous gout of the thoracic apine presenting as back pain and fever. J Clin Rheumatol 1999; 5: 335–341.
- 20 Kaye PV, Dreyer MD. spinal gout: an unusual clinical and cytological presentation. Cytopathology 1999; 10: 411–414.
- 21 Kao MC, Huang SC, Chiu CT, Yao YT. Thoracic cord compression due to gout: a case report and literature review. J Formos Med Assoc 2000; 99: 572–575.
- 22 St George E, Hillier CE, Hatfield R. Spinal cord compression: an unusual neurological complication of gout. *Rheumatology (Oxford)* 2001; **40**: 711–712.
- 23 Wang LC, Hung YC, Lee EJ, Chen HH. Acute paraplegia in a patient with spinal tophi: a case report. J Formos Med Assoc 2001; 100: 205–208.
- 24 Hsu CY, Shih TT, Huang KM, Chen PQ, Sheu JJ, Li YW. Tophaceous gout of the spine: MR imaging features. *Clin Radiol* 2002; **57**: 919–925.
- 25 Souza AW, Fontenele S, Carrete H Jr, Fernandes AR, Ferrari AJ. Involvement of the thoracic spine in tophaceous gout. A case report. *Clin Exp Rheumatol* 2002; 20: 228–230.
- 26 EI Sandid M, Ta H. Another presentation of gout. Ann Intern Med 2004; 140: W32.
- 27 Popovich T, Carpenter JS, Rai AT, Carson LV, Williams HJ, Marano GD. Spinal cord compression by tophaceous gout with fluorodeoxyglucose-positron-emission tomographic/MR fusion imaging. AJNR Am J Neuroradiol 2006; 27: 1201–1203.
- 28 Kwan BY, Osman S, Barra L. Spinal gout in a young patient with involvement of thoracic, lumbar and sacroiliac regions. *Joint Bone Spine* 2013; 80: 667–668.
- 29 Nasseri F, Myers A, Shah K, Moron FE. Severe back pain and lower extremities weakness in a young male. Br J Radiol 2013; 86: 20110685.
- 30 Yoon JW, Park KB, Park H, Kang DH, Lee CH, Hwang SH et al. Tophaceous gout of the spine causing neural compression. Korean J Spine 2013; 10: 185–188.
- 31 Konatalapalli RM, Demarco PJ, Jelinek JS, Murphey M, Gibson M, Jennings B et al. Gout in the axial skeleton. J Rheumatol 2009; 36: 609–613.
- 32 Konatalapalli RM, Lumezanu E, Jelinek JS, Murphey MD, Wang H, Weinstein A. Correlates of axial gout: a cross-sectional study. J Rheumatol 2012; 39: 1445–1449.
- 33 Beier CP, Hartmann A, Woertgen C, Brawanski A, Rothoerl RD. A large, erosive intraspinal and paravertebral gout tophus. Case report. J Neurosurg Spine 2005; 3: 485–487.
- 34 Draganescu M, Leventhal LJ. Spine gout: case report and review of the literature. J Clin Rheumatol 2004; 10: 74–79.
- 35 Mahmud T, Basu D, Dyson PH. Crystal arthropathy of the lumbar spine. J Bone Joint Surg Br 2005; 87: 513–517.
- 36 Suk KS, Kim KT, Lee SH, Park SW, Park YK. Tophaceous gout of the lumbar spine mimicking pyogenic discitis. Spine J 2007; 7: 94–99.
- 37 See LC, Kuo CF, Chuang FH, Shen YM, Ko YS, Chen YM *et al.* Hyperuricemia and metabolic syndrome: associations with chronic kidney disease. *Clin Rheumatol* 2011; **30**: 323–330.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons

license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http:// creativecommons.org/licenses/by/4.0/

886

Spinal Cord